No Prescription |
 |
 | ||
|
Brufen SR Generic Ibuprofen |
|
| ||
No Prescription » Prescription Drugs 3 » Brufen SR Generic Ibuprofen Ibuprofen is a nonsteroidal anti-inflammatory agent that possesses analgesic and antipyretic activities. Ibuprofen provide symptomatic relief of inflammation and pain in rheumatoid arthritis osteoarthritis and allied conditions.Brufen is also indicated for the relief of acute and/or chronic pain states in which there is an inflammatory component. Buy Brufen SR Generic Ibuprofen and other Prescription Drugs 3 products online at Medstore. 5435
About Brufen SR Generic Ibuprofen: Product Type: Prescription Drugs 3 Brufen SR( Generic Ibuprofen ) Brufen SR (Generic Ibuprofen) Generic Ibuprofen 800mg 30 Tablets Generic Ibuprofen Brufen SR
View more Prescription Drugs 3 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
